Investigation of the effect of saffron on asthma

Investigation of the effect of saffron supplementation on the some immunologic factors and oxidative Stress in patients with moderate persistent allergic asthma

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180418039354N1

Enrollment

Registered

2018-06-02

Start date

2018-06-05

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate persistent allergic asthma. Moderate persistent allergic asthma

Interventions

Intervention 1: Intervention group: consumption 100 mg of saffron (capsule) per day (two 50 mg capsule per day). Intervention 2: Control group: consumption two capsules containing starch per day.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 18 to 65 years old Moderate persistent allergic asthma according to the physician Normal body mass index (up to 27)

Exclusion criteria

Exclusion criteria: Smoking Diabetes Pregnancy and lactation Autoimmune disease, malignancies, gastrointestinal, liver and kidney disease, pneumonia and other pulmonary disease Taking antioxidant supplements Unwilling to continue the study

Design outcomes

Primary

Measure	Time frame
Interleukin 10 (IL-10). Timepoint: The beginning and end of supplementation. Method of measurement: ELISA method.;Transforming growth factor ß (TGF-ß). Timepoint: The beginning and end of supplementation. Method of measurement: ELISA method.;Interleukin 35 (IL-35). Timepoint: The beginning and end of supplementation. Method of measurement: ELISA method.;Prooxidant-antioxidant Balance (PAB). Timepoint: The beginning and end of supplementation. Method of measurement: ELISA method.	—

Measure

Time frame

Interleukin 10 (IL-10). Timepoint: The beginning and end of supplementation. Method of measurement: ELISA method.;Transforming growth factor ß (TGF-ß). Timepoint: The beginning and end of supplementation. Method of measurement: ELISA method.;Interleukin 35 (IL-35). Timepoint: The beginning and end of supplementation. Method of measurement: ELISA method.;Prooxidant-antioxidant Balance (PAB). Timepoint: The beginning and end of supplementation. Method of measurement: ELISA method.

—

Secondary

Measure	Time frame
Complete Blood Count-differential (CBC-diff). Timepoint: The beginning and end of the supplementation. Method of measurement: Will be assessed by Sysmex device.;A frequency of shortness of breath in the day or night. Timepoint: The beginning and end of the supplementation. Method of measurement: Based on the patient's response (number per week).;How often do you wake up because of asthma symptoms. Timepoint: The beginning and end of the supplementation. Method of measurement: Based on the patient's response (number per week).;Frequency of activity limitation due to asthma and shortness of breath. Timepoint: The beginning and end of the supplementation. Method of measurement: Based on the patient's response (number per week).;The frequency of use of salbutamol spray. Timepoint: The beginning and end of the supplementation. Method of measurement: Based on the patient's response (number per week).	—

Measure

Time frame

Complete Blood Count-differential (CBC-diff). Timepoint: The beginning and end of the supplementation. Method of measurement: Will be assessed by Sysmex device.;A frequency of shortness of breath in the day or night. Timepoint: The beginning and end of the supplementation. Method of measurement: Based on the patient's response (number per week).;How often do you wake up because of asthma symptoms. Timepoint: The beginning and end of the supplementation. Method of measurement: Based on the patient's response (number per week).;Frequency of activity limitation due to asthma and shortness of breath. Timepoint: The beginning and end of the supplementation. Method of measurement: Based on the patient's response (number per week).;The frequency of use of salbutamol spray. Timepoint: The beginning and end of the supplementation. Method of measurement: Based on the patient's response (number per week).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Bahreini

Ahvaz University of Medical Sciences

Bahreini.m@ajums.ac.ir+98 61 3373 8499

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026